User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.

Primary tabs

download
  • Open access
  • PDF
  • 586.05 K
Legssyer, Rachida Huaux, François [UCL] Lebacq, Jean [UCL] Delos, Monique [UCL] Marbaix, Etienne [UCL] Lebecque, Patrick [UCL] Lison, Dominique [UCL] Wallemacq, Pierre [UCL] Leal, Teresinha [UCL]

BACKGROUND: Inflammation plays a critical role in lung disease development and progression in cystic fibrosis. Azithromycin is used for the treatment of cystic fibrosis lung disease, although its mechanisms of action are poorly understood. We tested the hypothesis that azithromycin modulates lung inflammation in cystic fibrosis mice. METHODS: We monitored cellular and molecular inflammatory markers in lungs of cystic fibrosis mutant mice homozygous for the DeltaF508 mutation and their littermate controls, either in baseline conditions or after induction of acute inflammation by intratracheal instillation of lipopolysaccharide from Pseudomonas aeruginosa, which would be independent of interactions of bacteria with epithelial cells. The effect of azithromycin pretreatment (10 mg/kg/day) given by oral administration for 4 weeks was evaluated. RESULTS: In naive cystic fibrosis mice, a spontaneous lung inflammation was observed, characterized by macrophage and neutrophil infiltration, and increased intra-luminal content of the pro-inflammatory cytokine macrophage inflammatory protein-2. After induced inflammation, cystic fibrosis mice combined exaggerated cellular infiltration and lower anti-inflammatory interleukin-10 production. In cystic fibrosis mice, azithromycin attenuated cellular infiltration in both baseline and induced inflammatory condition, and inhibited cytokine (tumor necrosis factor-alpha and macrophage inflammatory protein-2) release in lipopolysaccharide-induced inflammation. CONCLUSION: Our findings further support the concept that inflammatory responses are upregulated in cystic fibrosis. Azithromycin reduces some lung inflammation outcome measures in cystic fibrosis mice. We postulate that some of the benefits of azithromycin treatment in cystic fibrosis patients are due to modulation of lung inflammation.

  1. Kerem B, Rommens J., Buchanan J., Markiewicz D, Cox T., Chakravarti A, Buchwald M, Tsui L., Identification of the cystic fibrosis gene: genetic analysis, 10.1126/science.2570460
  2. Riordan, Rommens J., Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J., et al., Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, 10.1126/science.2475911
  3. Stutts M. Jackson, Rossier Bernard C., Boucher Richard C., Cystic Fibrosis Transmembrane Conductance Regulator Inverts Protein Kinase A-mediated Regulation of Epithelial Sodium Channel Single Channel Kinetics, 10.1074/jbc.272.22.14037
  4. Mohler Peter J., Kreda Silvia M., Boucher Richard C., Sudol Marius, Stutts M. Jackson, Milgram Sharon L., Yes-Associated Protein 65 Localizes P62c-Yesto the Apical Compartment of Airway Epithelia by Association with Ebp50, 10.1083/jcb.147.4.879
  5. Awayda M. S., Regulation of Epithelial Sodium Channels by the Cystic Fibrosis Transmembrane Conductance Regulator, 10.1074/jbc.271.9.4725
  6. Schwiebert E. M., Morales M. M., Devidas S., Egan M. E., Guggino W. B., Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator, 10.1073/pnas.95.5.2674
  7. Lukacs GL, Mohamed A, Kartner N, Chang X-B, Riordan JR, Grinstein S: Conformational maturation of CFTR but not its mutant counterpart (ΔF508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994, 13:6076–6086.
  8. Stern Robert C., The Diagnosis of Cystic Fibrosis, 10.1056/nejm199702133360707
  9. Pamukcu A., Bush A., Buchdahl R., Effects ofPseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis, 10.1002/ppul.1950190103
  10. Henry Richard L., Mellis Craig M., Petrovic Lea, MucoidPseudomonas aeruginosa is a marker of poor survival in cystic fibrosis, 10.1002/ppul.1950120306
  11. Chmiel James F, Konstan Michael W, Anti-Inflammatory Medications for Cystic Fibrosis Lung Disease : Selecting the Most Appropriate Agent, 10.2165/00151829-200504040-00004
  12. Dinwiddie Robert, Anti-inflammatory therapy in cystic fibrosis, 10.1016/j.jcf.2005.05.010
  13. Jaffé Adam, Francis Jackie, Rosenthal Mark, Bush Andrew, Long-term azithromycin may improve lung function in children with cystic fibrosis, 10.1016/s0140-6736(05)78360-4
  14. Wolter J, Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial, 10.1136/thorax.57.3.212
  15. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M, Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial, 10.1016/s0140-6736(02)11081-6
  16. Saiman Lisa, Marshall Bruce C., Mayer-Hamblett Nicole, Burns Jane L., Quittner Alexandra L., Cibene Debra A., Coquillette Sarah, Fieberg Ann Yunker, Accurso Frank J., Campbell III Preston W., for the Macrolide Study Group, Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa : A Randomized Controlled Trial, 10.1001/jama.290.13.1749
  17. Gillis R. J., Iglewski B. H., Azithromycin Retards Pseudomonas aeruginosa Biofilm Formation, 10.1128/jcm.42.12.5842-5845.2004
  18. Kita Eiji, Sawaki Masayoshi, Oku Daisuke, Hamuro Akiko, Mikasa Keiichi, Konishi Mitsuru, Emoto Masashi, Takeuchi Shoji, Narita Nobuhiro, Kashiba Shuzo, Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin, 10.1093/jac/27.3.273
  19. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunga T, Ohno A, Miyazaki S, Yamaguchi K: Direct evidence for antipseudomonal activity of macrolides: exposure dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother 1996, 40:2271–2275.
  20. Imamura Y., Higashiyama Y., Tomono K., Izumikawa K., Yanagihara K., Ohno H., Miyazaki Y., Hirakata Y., Mizuta Y., Kadota J.-i., Iglewski B. H., Kohno S., Azithromycin Exhibits Bactericidal Effects on Pseudomonas aeruginosa through Interaction with the Outer Membrane, 10.1128/aac.49.4.1377-1380.2005
  21. Pier G. B., Grout M., Zaidi T. S., Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung, 10.1073/pnas.94.22.12088
  22. Schroeder T. H., Lee M. M., Yacono P. W., Cannon C. L., Gerceker A. A., Golan D. E., Pier G. B., CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF- B translocation, 10.1073/pnas.092160899
  23. Pier G, CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection, 10.1016/s1369-5274(02)00290-4
  24. van Doorninck JH, French PJ, Verbeek E, Peters RHPC, Morreau H, Bijman J, Scholte BJ: A mouse model for the cystic fibrosis ΔF508 mutation. EMBO J 1995, 14:4403–4411.
  25. Nicklas W., Baneux P., Boot R., Decelle T., Deeny A. A., Fumanelli M., Illgen-Wilcke B., Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units, 10.1258/0023677021911740
  26. Huaux F., Liu T., McGarry B., Ullenbruch M., Phan S. H., Dual Roles of IL-4 in Lung Injury and Fibrosis, 10.4049/jimmunol.170.4.2083
  27. Arras Mohammed, Huaux François, Vink Anne, Delos Monique, Coutelier Jean-Paul, Many Marie-Christine, Barbarin Virginie, Renauld Jean-Christophe, Lison Dominique, Interleukin-9 Reduces Lung Fibrosis and Type 2 Immune Polarization Induced by Silica Particles in a Murine Model, 10.1165/ajrcmb.24.4.4249
  28. Naito Yuji, Yoshikawa Toshikazu, Matsuyama Kiichi, Yagi Nobuaki, Arai Masahiro, Nakamura Yasunari, Kaneko Toshiro, Yoshida Norimasa, Kondo Motoharu, Neutrophils, Lipid Peroxidation, and Nitric Oxide in Gastric Reperfusion Injury in Rats, 10.1016/s0891-5849(97)00323-7
  29. Lasfargues G., Lardot C., Delos M., Lauwerys R., Lison D., The Delayed Lung Responses to Single and Repeated Intratracheal Administration of Pure Cobalt and Hard Metal Powder in the Rat, 10.1006/enrs.1995.1032
  30. Hoiby N, Diffuse panbronchiolitis and cystic fibrosis: East meets West., 10.1136/thx.49.6.531
  31. Koyama H., Geddes D. M., Erythromycin and diffuse panbronchiolitis, 10.1136/thx.52.10.915
  32. Jaffé Adam, Bush Andrew, Anti‐inflammatory effects of macrolides in lung disease, 10.1002/ppul.1076
  33. Pradal U., Delmarco A., Morganti M., Cipolli M., Mini E., Cazzola G., Long Term Azithromycin in Cystic Fibrosis: Another Possible Mechanism of Action?, 10.1179/joc.2005.17.4.393
  34. Barker Pierre M., Gillie Daniel J., Schechter Michael S., Rubin Bruce K., Effect of Macrolides onIn VivoIon Transport across Cystic Fibrosis Nasal Epithelium, 10.1164/rccm.200311-1508oc
  35. Equi Amanda C., Davies Jane C., Painter Hazel, Hyde Stephen, Bush Andrew, Geddes Duncan M., Alton Eric W.F.W., Exploring the mechanisms of macrolides in cystic fibrosis, 10.1016/j.rmed.2005.07.016
  36. Snouwaert J. N., Brigman K. K., Latour A. M., Malouf N. N., Boucher R. C., Smithies O., Koller B. H., An Animal Model for Cystic Fibrosis Made by Gene Targeting, 10.1126/science.257.5073.1083
  37. Dorin Julia R., Dickinson Paul, Alton Eric W. F. W., Smith Stephen N., Geddes Duncan M., Stevenson Barbara J., Kimber Wendy L., Fleming Stewart, Clarke Alan R., Hooper Martin L., Anderson Louise, Beddington Rosa S. P., Porteous David J., Cystic fibrosis in the mouse by targeted insertional mutagenesis, 10.1038/359211a0
  38. Delaney SJ, Alton EW, Smith SN, Lunn DP, Farley R, Lovelock PK, Thomson SA, Hume DA, Lamb D, Porteus DJ, Dorin JR, Wainwright BJ: Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J 1996, 15:955–963.
  39. Colledge William H., Abella Benjamin S., Southern Kevin W., Ratcliff Rosemary, Jiang Canwen, Cheng Seng H., MacVinish Lesley J., Anderson Janice R., Cuthbert Alan W., Evans Martin J., Generation and characterization of a ΔF508 cystic fibrosis mouse model, 10.1038/ng0895-445
  40. Zeiher B G, Eichwald E, Zabner J, Smith J J, Puga A P, McCray P B, Capecchi M R, Welsh M J, Thomas K R, A mouse model for the delta F508 allele of cystic fibrosis., 10.1172/jci118253
  41. Durie Peter R., Kent Geraldine, Phillips M. James, Ackerley Cameron A., Characteristic Multiorgan Pathology of Cystic Fibrosis in a Long-Living Cystic Fibrosis Transmembrane Regulator Knockout Murine Model, 10.1016/s0002-9440(10)63234-8
  42. Kent G, Iles R, Bear C E, Huan L J, Griesenbach U, McKerlie C, Frndova H, Ackerley C, Gosselin D, Radzioch D, O'Brodovich H, Tsui L C, Buchwald M, Tanswell A K, Lung disease in mice with cystic fibrosis., 10.1172/jci119861
  43. Zahm JM, Gaillard D, Dupuit F, Hinnarasky J, Porteous D, Dorin JR, Puchelle E: Early alterations in airway mucociliary clearence and inflammation of the lamina propria in CF mice. Am J Physiol 1997, 272:C853–859.
  44. Heeckeren A, Walenga R, Konstan M W, Bonfield T, Davis P B, Ferkol T, Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa., 10.1172/jci119828
  45. Scholte Bob J., Davidson Donald J., Wilke Martina, de Jonge Hugo R., Animal models of cystic fibrosis, 10.1016/j.jcf.2004.05.039
  46. Grubb BR, Boucher RC: Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999, 79:S193-S214.
  47. van Heeckeren Anna M., Schluchter Mark D., Xue Wei, Davis Pamela B., Response to Acute Lung Infection with MucoidPseudomonas aeruginosain Cystic Fibrosis Mice, 10.1164/rccm.200506-917oc
  48. Schroeder T. H., Reiniger N., Meluleni G., Grout M., Coleman F. T., Pier G. B., Transgenic Cystic Fibrosis Mice Exhibit Reduced Early Clearance of Pseudomonas aeruginosa from the Respiratory Tract, 10.4049/jimmunol.166.12.7410
  49. Coleman F. T., Mueschenborn S., Meluleni G., Ray C., Carey V. J., Vargas S. O., Cannon C. L., Ausubel F. M., Pier G. B., Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection, 10.1073/pnas.0437901100
  50. Yu H., Nasr S. Z., Deretic V., Innate Lung Defenses and Compromised Pseudomonas aeruginosa Clearance in the Malnourished Mouse Model of Respiratory Infections in Cystic Fibrosis, 10.1128/iai.68.4.2142-2147.2000
  51. van Heeckeren A. M., Schluchter M., Xue L., Alvarez J., Freedman S., St. George J., Davis P. B., Nutritional Effects on Host Response to Lung Infections with Mucoid Pseudomonas aeruginosa in Mice, 10.1128/iai.72.3.1479-1486.2004
  52. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075–1082.
  53. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., Fick R., The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis, 10.1002/ppul.1950200203
  54. Noah T. L., Black H. R., Cheng P.-W., Wood R. E., Leigh M. W., Nasal and Bronchoalveolar Lavage Fluid Cytokines in Early Cystic Fibrosis, 10.1093/infdis/175.3.638
  55. Tirouvanziam Rabindra, de Bentzmann Sophie, Hubeau Cédric, Hinnrasky Jocelyne, Jacquot Jacky, Péault Bruno, Puchelle Edith, Inflammation and Infection in Naive Human Cystic Fibrosis Airway Grafts, 10.1165/ajrcmb.23.2.4214
  56. Armstrong David S., Hook Sarah M., Jamsen Kris M., Nixon Gillian M., Carzino Rosemary, Carlin John B., Robertson Colin F., Grimwood Keith, Lower Airway Inflammation in Infants with Cystic Fibrosis Detected by Newborn Screening, 10.1002/ppul.20294
  57. Konstan M W, Hilliard K A, Norvell T M, Berger M, Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation., 10.1164/ajrccm.150.2.8049828
  58. Armstrong D. S, Grimwood K., Carzino R., Carlin J. B, Olinsky A., Phelan P. D, Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis, 10.1136/bmj.310.6994.1571
  59. Bonfield Tracey L., Konstan Michael W., Berger Melvin, Altered respiratory epithelial cell cytokine production in cystic fibrosis☆☆☆★, 10.1016/s0091-6749(99)70116-8
  60. Tabary Olivier, Zahm Jean Marie, Hinnrasky Jocelyne, Couetil Jean Paul, Cornillet Pascale, Guenounou Moncef, Gaillard Dominique, Puchelle Edith, Jacquot Jacky, Selective Up-Regulation of Chemokine IL-8 Expression in Cystic Fibrosis Bronchial Gland Cells in Vivo and in Vitro, 10.1016/s0002-9440(10)65633-7
  61. Kammouni W, Figarella C, Marchand S, Merten M: Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect Immun 1997, 65:5176–5183.
  62. Corvol Harriet, Fitting Catherine, Chadelat Katarina, Jacquot Jacky, Tabary Olivier, Boule Michele, Cavaillon Jean-Marc, Clement Annick, Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis, 10.1152/ajplung.00156.2002
  63. Matheson N.R., Wong P.S., Travis J., Enzymatic inactivation of human alpha-1-proteinase inhibitor by neutrophil myeloperoxidase, 10.1016/0006-291x(79)92062-x
  64. Clark RA, Stone PJ, Hag AE, Calore JD, Franzblau C: Myeloperoxydase-catalysed inactivation of α1-proteinase inhibitor by human neutrophils. J Biol Chem 1981, 256:3348–3353.
  65. Heinecke J W, Li W, Francis G A, Goldstein J A, Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins., 10.1172/jci116531
  66. Garner Hart P., Phillips James R., Herron Jean G., Severson Susan J., Milla Carlos E., Regelmann Warren E., Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis, 10.1016/j.lab.2004.04.010
  67. Koller D Y, Gotz M, Wojnarowski C, Eichler I, Relationship between disease severity and inflammatory markers in cystic fibrosis., 10.1136/adc.75.6.498
  68. Johnson Larry G., Vanhook Miriam K., Coyne Carolyn B., Haykal-Coates Najwa, Gavett Stephen H., Safety and Efficiency of Modulating Paracellular Permeability to Enhance Airway Epithelial Gene TransferIn Vivo, 10.1089/104303403765255138
  69. Ferretti S., Bonneau O., Dubois G. R., Jones C. E., Trifilieff A., IL-17, Produced by Lymphocytes and Neutrophils, Is Necessary for Lipopolysaccharide-Induced Airway Neutrophilia: IL-15 as a Possible Trigger, 10.4049/jimmunol.170.4.2106
  70. Freedman Steven D., Weinstein Deborah, Blanco Paola G., Martinez-Clark Pedro, Urman Serge, Zaman Munir, Morrow Jason D., Alvarez Juan G., Characterization of LPS-induced lung inflammation incftr−/−mice and the effect of docosahexaenoic acid, 10.1152/japplphysiol.00927.2001
  71. Bonfield T L, Panuska J R, Konstan M W, Hilliard K A, Hilliard J B, Ghnaim H, Berger M, Inflammatory cytokines in cystic fibrosis lungs., 10.1164/ajrccm.152.6.8520783
  72. Bonfield T L, Konstan M W, Burfeind P, Panuska J R, Hilliard J B, Berger M, Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis., 10.1165/ajrcmb.13.3.7544594
  73. Saadane Aicha, Soltys Jindrich, Berger Melvin, Role of IL-10 deficiency in excessive nuclear factor-κB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice, 10.1016/j.jaci.2004.10.044
  74. CHMIEL JAMES F., KONSTAN MICHAEL W., KNESEBECK JEANNE E., HILLIARD JAY B., BONFIELD TRACEY L., DAWSON DEBORAH V., BERGER MELVIN, IL-10 Attenuates Excessive Inflammation in ChronicPseudomonasInfection in Mice, 10.1164/ajrccm.160.6.9901043
  75. Chmiel James F., Konstan Michael W., Saadane Aicha, Krenicky Jeanne E., Lester Kirchner H., Berger Melvin, Prolonged Inflammatory Response to AcutePseudomonasChallenge in Interleukin-10 Knockout Mice, 10.1164/ajrccm.165.8.2107051
  76. Saadane Aicha, Soltys Jindrich, Berger Melvin, Role of IL-10 deficiency in excessive nuclear factor-κB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice, 10.1016/j.jaci.2004.10.044
  77. Tabary O., Escotte S., Couetil J. P., Hubert D., Dusser D., Puchelle E., Jacquot J., High Susceptibility for Cystic Fibrosis Human Airway Gland Cells to Produce IL-8 Through the I B Kinase   Pathway in Response to Extracellular NaCl Content, 10.4049/jimmunol.164.6.3377
  78. Barnes Peter J., Karin Michael, Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases, 10.1056/nejm199704103361506
  79. Wright Jeffrey G., Christman John W., The Role of Nuclear Factor Kappa B in the Pathogenesis of Pulmonary Diseases: Implications for Therapy, 10.1007/bf03256650
  80. Beringer P., Huynh K. M. T., Kriengkauykiat J., Bi L., Hoem N., Louie S., Han E., Nguyen T., Hsu D., Rao P. A., Shapiro B., Gill M., Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis, 10.1128/aac.49.12.5013-5017.2005
  81. Everard M.L., Sly P., Brenan S., Ryan G., Macrolide antibiotics in diffuse panbronchiolitis and in cystic fibrosis, 10.1183/09031936.97.10122926
  82. Tsai Wan C., Rodriguez Michael L., Young Katherine S., Deng Jane C., Thannickal Victor J., Tateda Kazuhiro, Hershenson Marc B., Standiford Theodore J., Azithromycin Blocks Neutrophil Recruitment inPseudomonasEndobronchial Infection, 10.1164/rccm.200402-200oc
  83. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman JM, Standiford : Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995, 155:722–729.
  84. van der Poll T., Marchant A., Keogh C. V., Goldman M., Lowry S. F., Interieukin-10 Impairs Host Defense in Murine Pneumococcal Pneumonia, 10.1093/infdis/174.5.994
Bibliographic reference Legssyer, Rachida ; Huaux, François ; Lebacq, Jean ; Delos, Monique ; Marbaix, Etienne ; et. al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.. In: Respiratory research, Vol. 7, p. 134 (2006)
Permanent URL http://hdl.handle.net/2078.1/10761